DexCom Net Income From Continuing Ops from 2010 to 2026
| DXCM Stock | USD 71.63 0.90 1.24% |
Net Income From Continuing Ops | First Reported 2003-12-31 | Previous Quarter 179.8 M | Current Value 283.8 M | Quarterly Volatility 73.5 M |
Check DexCom financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DexCom's main balance sheet or income statement drivers, such as Interest Expense of 12.2 M, Other Operating Expenses of 4.1 B or Operating Income of 724.5 M, as well as many indicators such as Price To Sales Ratio of 8.52, Dividend Yield of 0.0 or PTB Ratio of 10.1. DexCom financial statements analysis is a perfect complement when working with DexCom Valuation or Volatility modules.
DexCom | Net Income From Continuing Ops | Build AI portfolio with DexCom Stock |
Evaluating DexCom's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into DexCom Inc's fundamental strength.
Latest DexCom's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of DexCom Inc over the last few years. It is DexCom's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DexCom's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
DexCom Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 180,588,206 | |
| Coefficient Of Variation | 165.13 | |
| Mean Deviation | 262,042,619 | |
| Median | (22,400,000) | |
| Standard Deviation | 298,208,956 | |
| Sample Variance | 88928.6T | |
| Range | 822.9M | |
| R-Value | 0.87 | |
| Mean Square Error | 23637.3T | |
| R-Squared | 0.75 | |
| Slope | 51,170,078 | |
| Total Sum of Squares | 1422857.3T |
DexCom Net Income From Continuing Ops History
About DexCom Financial Statements
DexCom investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how DexCom Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 662.6 M | 695.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of DexCom Correlation against competitors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.